Looking for Her (2+)? A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer.

Looking for Her (2+)? A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2018 Oct 15;: Authors: Petrou P Abstract INTRODUCTION: Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several sub-types of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a monoclonal antibody, has proved its safety and efficacy in this specific subtype, nevertheless its high cost urges for caution among payers. Areas covered: The scope of this study is to systematically search and critically assess the economic evaluation studies of trastuzumab in patients with early stage Her2+ breast cancer. Expert Commentary: In the majority of the studies trastuzumab was found to be cost-effective. Its cost-effectiveness profile is contingent to treatment duration, benefit effect and age of the patient. PMID: 30320510 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research